DEFEROXAMINE MESILATE ( DrugBank: Deferoxamine )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
286遺伝性鉄芽球性貧血2

286. 遺伝性鉄芽球性貧血


臨床試験数 : 7 薬物数 : 23 - (DrugBank : 10) / 標的遺伝子数 : 8 - 標的パスウェイ数 : 42
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2010-021062-29-GR
(EUCTR)
12/04/201102/02/2011Phase II, open-label, single-arm, multicenter study to evaluate the efficacy and safety of deferasirox in combination with deferoxamine followed by deferasirox monotherapy in patients with severe cardiac iron overload due to chronic blood transfusion (HYPERION) - HYPERIONPhase II, open-label, single-arm, multicenter study to evaluate the efficacy and safety of deferasirox in combination with deferoxamine followed by deferasirox monotherapy in patients with severe cardiac iron overload due to chronic blood transfusion (HYPERION) - HYPERION transfusion-dependent patients with TM, DBA or congenital sideroblastic anemia with severe cardiac iron overload
MedDRA version: 13.1;Level: LLT;Classification code 10065974;Term: Chronic iron overload;System Organ Class: 10027433 - Metabolism and nutrition disorders
Trade Name: Exjade
Product Name: Exjade
Product Code: ICL670
INN or Proposed INN: DEFERASIROX
Other descriptive name: Exjade
Trade Name: Exjade
Product Name: Exjade
Product Code: ICL670
INN or Proposed INN: DEFERASIROX
Other descriptive name: Exjade
Trade Name: Exjade
Product Name: Exjade
Product Code: ICL670
INN or Proposed INN: DEFERASIROX
Other descriptive name: Exjade
Trade Name: Desferal
Product Name: deferoxamine
Product Code: DFO
INN or Proposed INN: DEFEROXAMINE MESILATE
Trade Name: DESFERAL
Product Name: deferoxamine
Product Code: DFO
INN or Proposed INN: DEFEROXAMINE MESILATE
Novartis Pharma Services AGNULLNot RecruitingFemale: yes
Male: yes
45Phase 2Greece;Italy;United Kingdom
2EUCTR2010-021062-29-GB
(EUCTR)
21/12/201020/10/2010Phase II, open-label, single-arm, multicenter study to evaluate the efficacy and safety of deferasirox in combination with deferoxamine followed by deferasirox monotherapy in patients with severe cardiac iron overload due to chronic blood transfusion (HYPERION) - HYPERIONPhase II, open-label, single-arm, multicenter study to evaluate the efficacy and safety of deferasirox in combination with deferoxamine followed by deferasirox monotherapy in patients with severe cardiac iron overload due to chronic blood transfusion (HYPERION) - HYPERION transfusion-dependent patients with TM, DBA or congenital sideroblastic anemia with severe cardiac iron overload
MedDRA version: 14.1;Level: LLT;Classification code 10065974;Term: Chronic iron overload;System Organ Class: 10027433 - Metabolism and nutrition disorders
Trade Name: Exjade
Product Name: Exjade
Product Code: ICL670
INN or Proposed INN: DEFERASIROX
Other descriptive name: Exjade
Trade Name: Exjade
Product Name: Exjade
Product Code: ICL670
INN or Proposed INN: DEFERASIROX
Other descriptive name: Exjade
Trade Name: Exjade
Product Name: Exjade
Product Code: ICL670
INN or Proposed INN: DEFERASIROX
Other descriptive name: Exjade
Product Name: deferoxamine
Product Code: DFO
INN or Proposed INN: DEFEROXAMINE MESILATE
Product Name: deferoxamine
Product Code: DFO
INN or Proposed INN: DEFEROXAMINE MESILATE
Trade Name: Exjade
Product Name: Exjade
Product Code: ICL670
INN or Proposed INN: deferasirox
INN or Proposed INN: deferasirox
INN or Proposed INN: deferasirox
Novartis Pharma Services AGNULLNot RecruitingFemale: yes
Male: yes
45Phase 2Greece;Italy;United Kingdom